ADAM17 and metastatic malignant neoplasm in the lymph nodes: The elevated expression of ADAM17 was significantly associated with such characteristics as higher TNM stage (OR = 4.09, 95% CI 1.85–9.04; I2 = 84.1%; p = 0.000), lymph node metastasis (OR = 3.08, 95% CI 1.13–8.36; I2 = 79.7%; p = 0.007), and age (OR = 1.65, 95% CI 1.24–2.21; I2 = 0%; p = 0.692) (Figure 3, Figure 4 and Figure 5).